By Clinical Research News Staff

February 19, 2019 | Saama announced a new partnership with The Leukemia & Lymphoma Society (LLS) to accelerate the development of novel acute myeloid leukemia (AML) therapies through its Beat AML Master Clinical Trial. LLS will deploy Saama’s Life Science Analytics Cloud (LSAC) to enhance the operational and clinical conduct of the ongoing, multi-drug, multi-site precision medicine trial. The announcement came during the 10^th annual Summit for Clinical Ops Executives (SCOPE) in Orlando.

The Beat AML Master Clinical Trial’s innovative precision medicine approach employs comprehensive genomic profiling (CGP) to find and match specific AML genetic mutations in newly diagnosed patients over age 60 with an investigational drug or drug combination that is potentially best suited to attack the specific molecular mutations causing the cancer.

More than 20,000 Americans are diagnosed with AML, the most lethal of the blood cancers, and 10,000 die from AML annually. The five-year-survival rate for older adults remains dismal at less than 20 percent. Despite advances in treating other blood cancers, the standard of treatment for AML has remained the same for more than 40 years.

LLS has assembled a network of Beat AML partners, including the U.S. Food and Drug Administration (FDA), top cancer centers, multiple pharmaceutical companies, a contract research organization (CRO), and select technology experts, who have united to tackle AML.

“The team at The Leukemia & Lymphoma Society are pioneers when it comes to personalized medicine. Their position as a non-profit organization has allowed them to facilitate and execute a complex umbrella trial in close collaboration with a number of stakeholders,” Kenneth L. Massey, Chief Life Science Officer at Saama Technologies, said in a press release. “The life science industry as a whole is counting on their success, which will hopefully be the catalyst that fundamentally changes the way clinical trials are executed. We are equally excited and humbled to be given the opportunity to be part of this landmark trial.”

Editor’s Note: Saama is exhibiting at this week’s Summit for Clinical Ops Executives in Orlando. You can learn more at booth #314